Entera Bio Files Prospectus For Resale Of Up To 134,803,910 Ordinary Shares By Selling Shareholders From July Private Placement
https://www.sec.gov/Archives/edgar/data/1638097/000117891326004221/zk2635989.htm
Read original at benzingaStocks · News reference
Entera Bio Enters Into Securities Purchase Agreement For Oversubscribed Private Placement Financing, Expected To Result In Aggregate Gross Proceeds Of ~$275M
Expected gross proceeds are anticipated to extend the Company's cash runway into 2030 and fully support Phase 3 registrational studies for EB613, the first oral PTH(1-34) peptide tablet in development for the
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 27, 2026, 12:33 PM
- Checked
- Jul 27, 2026, 12:33 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — Entera Bio Ltd. (ENTX)
Filed: 2026-08-18 AccNo: 0001178913-26-004178 Size: 223 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgarEntera Bio Q2 EPS $(0.14) Misses $(0.08) Estimate
Read original at benzingaEntera Bio Intends To File Ind For EB612 In First Half Of 2027; EB613 Phase 3 Study Initiation Planned For Late 2026, Topline Data Anticipated In Second Half 2028
IND Enabling Studies Ongoing for EB612 - the First Oral Peptide Replacement Tablet in Development for Patients with Hypoparathyroidism – Intention to File IND in First Half of 2027
Read original at benzinga